PNH Clinical Case Review

Ilene C. Wetiz, MD, professor of clinical medicine at the Keck School of Medicine at the University of Southern California, discusses the treatment options for this case:

"How do we treat this? Well, complement inhibition, again, has been shown to be better than best supportive care, and the approved C5 inhibitors — approved by the FDA and EMA — are eculizumab or ravulizumab, and recently, pegcetacoplan (Empaveli, Apellis Pharmaceuticals) as a C3 inhibitor was also approved."